About

Pfizer has announced a research grant opportunity aimed at addressing critical gaps in understanding pneumococcal disease burden and serotype epidemiology in children in Saudi Arabia.

The focus of this grant includes surveillance studies on invasive and non-invasive pneumococcal disease serotype distribution in children under five years of age using samples collected between 2023 and 2029, investigation of genetic evolution of pneumococci following immunization programs with pneumococcal conjugate vaccines, and analysis of antibiotic sensitivity patterns of Streptococcus pneumoniae in young children.

This initiative highlights the ongoing need for comprehensive data despite two decades since the introduction of pneumococcal conjugate vaccines, as gaps in epidemiological documentation continue to limit informed public health decisions in Saudi Arabia. Applicants are encouraged to design studies using prospective or bidirectional cohort surveillance methods to generate robust and actionable data.

Eligible applicants must be organizations based in Saudi Arabia, with the Principal Investigator holding appropriate medical, scientific, nursing, or pharmacy qualifications and being affiliated with the applying institution. Collaborative, multicenter studies are encouraged, provided all participating entities have clearly defined roles and the primary applicant maintains a central role in the project.

Funding of up to 400,000 USD is available per project, with the possibility of higher funding considered on a case-by-case basis. The maximum duration for funded projects is three years, allowing sufficient time for meaningful data collection and analysis within the defined surveillance period.

Eligibility

This funding opportunity represents a significant step toward strengthening pediatric infectious disease surveillance and supporting evidence-based healthcare strategies in Saudi Arabia.

Post Date: April 07, 2026